Leap Therapeutics, Inc. (LPTX)
LPTX Stock Price Chart
Explore Leap Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze LPTX price movements and trends.
LPTX Company Profile
Discover essential business fundamentals and corporate details for Leap Therapeutics, Inc. (LPTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
25 Jan 2017
Employees
52.00
Website
https://www.leaptx.comCEO
Douglas E. Onsi
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
LPTX Financial Timeline
Browse a chronological timeline of Leap Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.24.
Earnings released on 14 Aug 2025
EPS came in at -$0.40 falling short of the estimated -$0.29 by -37.93%.
Earnings released on 13 May 2025
EPS came in at -$0.37 surpassing the estimated -$0.38 by +2.63%.
Earnings released on 26 Mar 2025
EPS came in at -$0.37 surpassing the estimated -$0.39 by +5.13%.
Earnings released on 13 Nov 2024
EPS came in at -$0.44 surpassing the estimated -$0.46 by +4.35%.
Earnings released on 12 Aug 2024
EPS came in at -$0.52 falling short of the estimated -$0.42 by -23.81%.
Earnings released on 13 May 2024
EPS came in at -$0.51 surpassing the estimated -$0.57 by +10.53%.
Earnings released on 18 Mar 2024
EPS came in at -$0.46 surpassing the estimated -$0.56 by +17.86%, while revenue for the quarter reached $634.00K .
Earnings released on 13 Nov 2023
EPS came in at -$0.51 falling short of the estimated -$0.48 by -6.25%.
Earnings released on 14 Aug 2023
EPS came in at -$0.91 surpassing the estimated -$0.98 by +7.14%.
Stock split effective on 21 Jun 2023
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2023
EPS came in at -$3.20 falling short of the estimated -$0.90 by -255.56%.
Earnings released on 24 Mar 2023
EPS came in at -$1.10 falling short of the estimated -$0.90 by -22.22%.
Earnings released on 14 Nov 2022
EPS came in at -$1.30 falling short of the estimated -$1.10 by -18.18%.
Earnings released on 12 Aug 2022
EPS came in at -$1.50 falling short of the estimated -$1.00 by -50.00%.
Earnings released on 13 May 2022
EPS came in at -$0.90 surpassing the estimated -$1.10 by +18.18%.
Earnings released on 11 Mar 2022
EPS came in at -$1.00 surpassing the estimated -$1.10 by +9.09%, while revenue for the quarter reached $375.00K , missing expectations by -2.85%.
Earnings released on 12 Nov 2021
EPS came in at -$1.40 falling short of the estimated -$1.10 by -27.27%, while revenue for the quarter reached $375.00K , beating expectations by +20.97%.
Earnings released on 13 Aug 2021
EPS came in at -$1.20 surpassing the estimated -$1.30 by +7.69%, while revenue for the quarter reached $375.00K , meeting expectations.
Earnings released on 14 May 2021
EPS came in at -$1.20 falling short of the estimated -$1.10 by -9.09%, while revenue for the quarter reached $375.00K , beating expectations by +10.00%.
Earnings released on 12 Mar 2021
EPS came in at -$0.90 falling short of the estimated -$0.80 by -12.50%, while revenue for the quarter reached $375.00K .
Earnings released on 12 Nov 2020
EPS came in at -$0.90 surpassing the estimated -$1.20 by +25.00%, while revenue for the quarter reached $375.00K .
LPTX Stock Performance
Access detailed LPTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.